Takeda Pharmaceutical (TAK) Interest Expenses (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Interest Expenses of -$400.6 million for Q2 2026, up 45.91% year-over-year from -$274.5 million in Q2 2025, and up 41.4% quarter-over-quarter from -$683.6 million in Q1 2026.
Takeda Pharmaceutical (TAK) Interest Expenses (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Interest Expenses history runs 10 years deep, the most recent figure standing at -$400.6 million for Q2 2026.
- In Q2 2026, Interest Expenses rose 45.91% year-over-year to -$400.6 million; the TTM figure through Jun 2026 stood at -$3.6 billion (down 21.67% YoY), while the FY2026 annual figure was $2.4 billion, up 72.25% from the prior year.
- Interest Expenses for Q2 2026 stood at -$400.6 million, up from -$683.6 million in the prior quarter.
- The five-year high for Interest Expenses was $2.2 billion in Q1 2022, with the low at -$2.1 billion in Q3 2025.
- The 5-year median for Interest Expenses is -$431.8 million (2022), against an average of -$495.5 million.
- The sharpest annual moves came in 2023 and 2026: Interest Expenses sank 206.97% in 2023, then surged 45.91% in 2026.
- Takeda Pharmaceutical's Interest Expenses stood at -$564.5 million in 2022, then jumped by 41.04% to -$332.8 million in 2023, then climbed by 0.6% to -$330.9 million in 2024, then decreased by 6.64% to -$352.8 million in 2025, then retreated by 13.53% to -$400.6 million in 2026.
- Business Quant data shows TAK's Interest Expenses at -$400.6 million in Q2 2026, -$683.6 million in Q1 2026, and -$352.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.78 Bn | 42.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.24 Bn | 39.59 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.66 Bn | 29.98 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.34 Bn | 19.68 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.80 Bn | 17.91 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.64 Bn | 15.25 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 59.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.25 Bn | 7.59 Bn | 397.90 Mn | 25.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -400.56 Mn |
| Jun 30, 2026 | -400.56 Mn |
| Mar 31, 2026 | -683.57 Mn |
| Mar 31, 2026 | -683.57 Mn |
| Dec 31, 2025 | -352.84 Mn |
| Dec 31, 2025 | -352.84 Mn |
| Sep 30, 2025 | -2.13 Bn |
| Sep 30, 2025 | -2.13 Bn |
| Jun 30, 2025 | -740.58 Mn |
| Jun 30, 2025 | -740.58 Mn |
| Mar 31, 2025 | -702.65 Mn |
| Mar 31, 2025 | -702.65 Mn |
| Dec 31, 2024 | -330.86 Mn |
| Dec 31, 2024 | -330.86 Mn |
| Sep 30, 2024 | -1.16 Bn |
| Sep 30, 2024 | -1.16 Bn |
| Jun 30, 2024 | -383.45 Mn |
| Jun 30, 2024 | -383.45 Mn |
| Mar 31, 2024 | -402.84 Mn |
| Mar 31, 2024 | -402.84 Mn |